Using our experience in RNA analysis, Quadrant, in partnership with SUNY Upstate Medical University, developed a COVID-19 saliva test. In the Fall of 2020, our COVID-19 Saliva Test was granted Emergency Use Authorization (EAU) from the Food and Drug Administration (FDA) where it is currently referenced as the most sensitive COVID-19 saliva test on the market.
During the height of the COVID-19 Pandemic, the need for more access to quality PCR testing arose, so Quadrant along with state and county officials worked together to create over 40 pop-up testing sites throughout NY State. Through this partnership, we were able to test and provide results for over four million New Yorkers.
Quadrant’s mission is to improve diagnostic accuracy and patient access to testing. As emerging infectious diseases become more prevalent with the potential to become a public health emergency, Quadrant will assess the community’s need for the development of additional diagnostic testing.
